Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 7/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | GPR6 | P46095 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20595262 | 1.00 | HCRTR1 (0.37) | HCRTR1HCRTR2KDM4ERAB9ANPC1 | |
| SCHEMBL20595261 | 0.90 | MAPT (0.38) | HCRTR1HCRTR2KDM4ERAB9ANPC1 | |
| SCHEMBL21800729 | 0.90 | MAPT (0.38) | HCRTR1HCRTR2KDM4ERAB9ANPC1 | |
| SCHEMBL3704769 | 0.89 | P2RX3 (0.42) | HCRTR1HCRTR2KDM4ERAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL2174735 | 0.88 | KDM4E (0.35) | HCRTR1HCRTR2KDM4ERAB9ANPC1 | |
| SCHEMBL20595603 | 0.86 | ACACB (0.37) | HCRTR1HCRTR2KDM4ERAB9ANPC1 | |
| SCHEMBL21800770 | 0.86 | LMNA (0.37) | HCRTR1HCRTR2KDM4ERAB9ANPC1 | |
| SCHEMBL21800655 | 0.86 | ACACB (0.37) | HCRTR1HCRTR2KDM4ERAB9ANPC1 | |
| SCHEMBL20595529 | 0.86 | LMNA (0.37) | HCRTR1HCRTR2KDM4ERAB9ANPC1 | |
| SCHEMBL20595495 | 0.85 | CYP1A2 (0.39) | HCRTR1HCRTR2KDM4ERAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230099018-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | UNIV MASSACHUSETTS (US) | 2023-03-30 | — | — | US | disclosed |
| US-20200087265-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | UNIV MASSACHUSETTS (US) | 2020-03-19 | — | — | US | disclosed |
| EP-2459582-B1 | HEPATITIS C VIRUS NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2015-05-27 | — | — | EP | disclosed |
| US-8828930-B2 | Hepatitis C virus NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-09-09 | — | — | US | disclosed |
| EP-2540350-B1 | COMBINATIONS OF A MACROCYCLIC QUINOXALINE COMPOUND WHICH IS AN HCV NS3 PROTEASE INHIBITOR WITH OTHER HCV AGENTS | MERCK SHARP & DOHME (US) | 2014-05-21 | — | — | EP | disclosed |
| EP-2540349-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A MACROCYCLIC QUINOXALINE COMPOUND WHICH IS AN HCV NS3 PROTEASE INHIBITOR | MERCK SHARP & DOHME (US) | 2014-02-12 | — | — | EP | disclosed |
| EP-2540350-A1 | Combinations of a macrocyclic quinoxaline compound which is an HCV NS3 protease inhibitors with other HCV agents | Merck Sharp & Dohme Corp. (US) | 2013-01-02 | — | — | EP | disclosed |
| EP-2540349-A1 | Pharmaceutical compositions comprising a macrocyclic quinoxaline compound which is an HCV NS3 protease inhibitor | Merck Sharp & Dohme Corp. (US) | 2013-01-02 | — | — | EP | disclosed |
| EP-2310095-B1 | MACROCYCLIC QUINOXALINE COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2012-08-29 | — | — | EP | disclosed |
| EP-2459582-A1 | HEPATITIS C VIRUS NS3 PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-06-06 | — | — | EP | disclosed |
| US-20120121624-A1 | HEPATITIS C VIRUS NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP (US) | 2012-05-17 | — | — | US | disclosed |
| US-8080654-B2 | Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors | Insituto di Ricerche di Biologia Molecolare P. Angeletti SpA (IT) | 2011-12-20 | — | — | US | disclosed |
| WO-2011014487-A1 | HEPATITIS C VIRUS NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-02-03 | — | — | WO | disclosed |
| US-20100029666-A1 | Macrocyclic Quinoxaline Compounds as HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2010-02-04 | — | — | US | disclosed |
| WO-2010011566-A1 | MACROCYCLIC QUINOXALINE COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087265-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | HAVCR2, CTSC, DPP4 | HCRTR1 3894/4885HCRTR2 4753/4885KDM4E 782/4885 |
| US-20120121624-A1 | HEPATITIS C VIRUS NS3 PROTEASE INHIBITORS | HAVCR2, GTF3C3, CTSC | HCRTR1 4191/4885HCRTR2 4693/4885KDM4E 3040/4885 |
| US-20230099018-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | HAVCR2, CTSC, DPP4 | HCRTR1 3894/4885HCRTR2 4753/4885KDM4E 782/4885 |
| US-20100029666-A1 | Macrocyclic Quinoxaline Compounds as HCV NS3 Protease Inhibitors | KEAP1, CTSC, SPINT2 | HCRTR1 3410/4885HCRTR2 4453/4885KDM4E 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.